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Inactivating mutations in the transcription factor hepatocyte
nuclear factor (HNF) 1AcauseHNF1A–maturity-onset diabetes
of the young (HNF1A-MODY), the most common monogenic
form of diabetes. To examine HNF1A-MODY-induced defects
in gene expression, we performed a microarray analysis of the
transcriptome of rat INS-1 cells inducibly expressing the com-
mon hot spot HNF1A frameshift mutation, Pro291fsinsC-
HNF1A. Real-time quantitative PCR (qPCR), Western blotting,
immunohistochemistry, reporter assays, and chromatin immu-
noprecipitation (ChIP) were used to validate alterations in gene
expression and to explore biological activities of target genes.
Twenty-four hours after induction of the mutant HNF1A pro-
tein, we identified a prominent down-regulation of the bone
morphogenetic protein 3 gene (Bmp-3) mRNA expression.
Reporter assays, qPCR, and Western blot analysis validated
these results. In contrast, inducible expression of wild-type
HNF1A led to a time-dependent increase in Bmp-3mRNA and
protein levels. Moreover, reduced protein levels of BMP-3 and
insulin were detected in islets of transgenic HNF1A-MODY
mice. Interestingly, treatment of naïve INS-1 cells or murine
organotypic islet cultures with recombinant human BMP-3
potently increased their insulin levels and restored the decrease
in SMAD2 phosphorylation and insulin gene expression
induced by theHNF1A frameshiftmutation. Our study suggests
a critical link between HNF1A-MODY-induced alterations in
Bmp-3 expression and insulin gene levels in INS-1 cells and
indicates that the reduced expression of growth factors involved
in tissue differentiationmayplay an important role in the patho-
physiology of HNF1A-MODY.
Maturity-onset diabetes of the young (MODY)2 is a familial
form of non-insulin-dependent diabetes with autosomal dom-
inant inheritance (1). Most forms of MODY are caused by
decreased expression of functional transcription factors lead-
ing to a decrease in beta cell mass and islet architecture (2).
Inactivating mutations in the transcription factor hepatocyte
nuclear factor (HNF) 1A cause HNF1A-MODY (3), the most
common monogenic form of diabetes (4). Pancreatic beta cell
dysfunction is a hallmark feature of the pathogenesis of
HNF1A-MODY and type 2 diabetes (5–7). The control of pan-
creatic differentiation by extracellular signaling molecules and
growth factors during development is an area of intensive
research (8). However, our knowledge on the role of extracel-
lular signaling molecules or growth factors in the pathogenesis
of HNF1A-MODY or type 2 diabetes is currently limited.
Cytokines of the transforming growth factor- (TGF-)
superfamily, which includes the TGF- isoforms, activins, and
the bone morphogenetic proteins (BMPs), regulate gene
expression in diverse cell types and are involved in numerous
processes including lineage determination, tissue differentia-
tion, cell proliferation, and apoptosis (9–11). TGF-/activin
and BMP signaling have been shown to play a critical role in
pancreatic development (12–14). Using an unbiased transcrip-
tomics approach in INS-1 cells inducibly expressing the
common human hot spot HNF1A frameshift mutation,
Pro291fsinsC-HNF1A, we demonstrate here that HNF1A con-
trols the expression of theTGF- superfamilymember, BMP-3.
We further demonstrate a role for BMP-3 in the control of
insulin expression with potential implications for HNF1A-
MODY pathophysiology.
EXPERIMENTAL PROCEDURES
Cell Culture: INS-1 Cells OverexpressingHNF1A in an Induc-
ible System—Rat INS-1 insulinoma cells overexpressing wild-
type HNF1A (WT-HNF1A), the HNF1A-MODY-associated* This work was supported by Health Research Board Grant RP/2008/14 andScience Foundation Ireland Grant 08/IN1/1949 (to J. H. M. P.) and Health
Research Board Grants RP/2004/220 and RP/2007/316 (to M. M. B.).
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frameshift mutant Pro291fsinsC-HNF1A, carrying a C nucleo-
tide insertion in a poly(C) tract mutation hot spot, or a domi-
nant negative mutant of HNF1A (DN-HNF1A/SM6) all under
the control of a doxycycline-dependent transcriptional activa-
tor have been described previously (15–17). Cells were cultured
in RPMI 1640medium at 6mMglucose supplementedwith 10%
fetal bovine serum (FBS) (PAA, Co¨lbe, Germany), 2 mM L-glu-
tamine, 1 mM pyruvate, penicillin (100 units/ml), streptomycin
(100 g/ml), 10 mM HEPES (pH 7.4), and 50 M 2-mercapto-
ethanol (Sigma) (18). For treatments with recombinant BMP-3
(rBMP-3), cells were cultured in 2% serum overnight and then
treated with vehicle or 500 ng/ml doxycycline and 10 ng/ml
rBMP-3 protein made up in 0.1% bovine serum albumin (BSA)
(R&D Systems Europe Ltd.) in 0.05% serum-containing
medium for 24 h.
Preparation of Mouse Organotypic Pancreatic Slice Cultures—
Animal experiments were carried out in accordance with the
principles of the European Communities Council Directive
(86/609/EEC) and the National Institute of Health Guide for
the Care and Use of Laboratory Animals. Procedures were
reviewed and approved by the research ethics committee of
the Royal College of Surgeons in Ireland, under license from
the Department of Health, Dublin, Ireland. Pancreatic slices
were obtained from C57BL/6J background mice. Mice were
sacrificed by abdominal injection of 40 mg/kg pentobarbital
(Dolethal; Ve´toquinol, Buckingham, UK). The abdominal cav-
ity was opened, and warm (37 °C) low gelling temperature aga-
rose (2% w/v, Seaplaque GTG-agarose, BMA Products, Augst,
Switzerland) was injected into the distally (duodenal side)
clamped bile duct. Prior to the injection a ligature was per-
formed at the height of the hepatic bifurcation of the bile duct
to prevent the injected agarose from flowing backward toward
the liver. During slicing and after the preparation, the tissuewas
kept in an ice-cold extracellular solution (125mMNaCl, 2.5mM
KCl, 26 mM NaHCO3, 1.25 mM Na2HPO4, 2 mM sodium pyru-
vate, 0.25 mM ascorbic acid, 3 mM myo-inositol, 6 mM lactic
acid, 1 mM MgCl2, 2 mM CaCl2, and 3 mM glucose) adjusted to
pH 7.3 by gassing with carbogen (95% O2, 5% CO2). The
injected and hardened pancreas was then extracted, placed in
ice-cold extracellular solution, and, if necessary, supported
with subcapsular injections of agarose. A small cube was cut
from the agarose-embedded pancreatic tissue and glued (Super
Glue; ND Industries, Troy, MI) onto the sample block of the
vibratome (Intracel Vibratome 1500, Herts, UK). The tissue
was sliced at a speed of 0.05 mm s1 and 75 Hz into 140-m-
thick slices of 1 1 cm.During slicing and for storage the tissue
slices were kept in ice cold extracellular solution and were
gassed continuously with carbogen. Slices were then placed on
the air-medium interface of Millicell semiporous membranes
(pore size of 0.4 m;Millipore) and incubated at 37 °C with 5%
CO2. Slices were left to recover in RPMI 1640 medium at 6 mM
glucose (as above) for at least 24 h in the incubator before treat-
ment. For experiments with BMP-3, cells were cultured in 2%
serum overnight and then treated with either vehicle or 50
ng/ml rBMP-3 protein made up in 0.1% BSA (R&D Systems
Europe Ltd.) in 0.05% serum-enriched media for 24 h.
Real-time Absolute RT-PCR—For the assessment of Hnf1a
expression by real-time quantitative PCR (qPCR) using abso-
lute copy numbers, an Hnf1a gene-specific PCR amplicon was
prepared as a standard. The calibration curve was created by
plotting the threshold cycle corresponding to each standard
versus their corresponding log number of Hnf1a standard
(expressed as cDNA copy number of theHnf1a gene). Normal-
ization was carried out using total RNA values (19).
Microarray Analyses—Total RNA of INS-1 insulinoma cells
overexpressing the Pro291fsinsC-HNF1A mutant for 24 h ver-
sus non-induced controls was extracted using the RNeasyMidi
kit (Qiagen) and reverse transcribed to cDNA using the Super-
script Choice kit (Invitrogen) with 20–40 g of total RNA as
template. The cRNA was prepared and biotin-labeled by in
vitro transcription (Enzo Biochemical, Farmingdale, NY) and
subsequently fragmented by incubation at 94 °C for 35 min in
the presence of fragmentation buffer (40 mM Tris acetate (pH
8.1), 100 mM potassium acetate, and 30 mM magnesium ace-
tate). Fifteen micrograms of fragmented cRNA was hybridized
for 16 h at 45 °C to a rat U34A array (Affymetrix, Santa Clara,
CA), and the gene chips were automatically washed and stained
with streptavidin-phycoerythrin by using a fluidics station.
Finally, probe arrays were scanned at 3-mm resolution using
the Genechip System confocal scanner (Aligent Technologies,
Palo Alto, CA). The Affymetrix Microarray Suite 5.0 was used
to scan and analyze the relative abundance of each gene from
the average difference of intensities. For each individual gene,
the signal ratio between perfect match and mismatch probe
cells was used to determine its “Absolute Call,” indicating
whether the corresponding transcript was present (P), absent
(A), or marginal (M). For analysis of differential target gene
expression, the “Difference Call Decision Matrix” was
employed. Individual transcript levels were ranked as either
increased (I),marginally increased (MI), decreased (D),margin-
ally decreased (MD), or not changed (NC). To be considered as
differentially regulated, the Absolute Call of individual tran-
scripts had to be present or marginal, and the Difference
Call increased/decreased or marginally increased/marginally
decreased. The gene identity of the obtained expressed
sequence tag sequences represented on the chips refers to the
assignment given on the Affymetrix Homepage, NetAffx Anal-
ysis Center. Expressed sequence tag sequences without given
gene identities were analyzed by PubMed database searches
(standard nucleotide-nucleotide BLAST) (20). The microarray
experiment was performed in duplicate with the threshold for
differentially expressed up- and down-regulated genes set at
1.5-fold/1.5-fold (median value of both samples) and 2.0-
fold/2.0-fold in at least one of the duplicate samples. The rat
RG-U34A0 microarray contains 7,000 full-length sequences
and 1,000 expressed sequence tags clusters. The data were
subsequently imported into dCHIP software.
Real-time qPCR—Expression patterns of L-type pyruvate
kinase, transmembrane protein27 (Tmem27), Bmp-3, Bmp-4,
and insulin gene mRNA were examined using qPCR. INS-1
cells were harvested from culture at the appropriate time
points. Total RNA was extracted using the RNeasy Mini kit
(Qiagen). First-strand cDNA synthesis was performed using 1
g of total RNA as template and Superscript II reverse tran-
scriptase (Invitrogen) primed with 50-pmol random hexamers
(New England Biolabs). Real-time qPCR was performed using
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the LightCycler 2.0 (Roche Diagnostics) and the QuantiTech
SYBR Green PCR kit (Qiagen) according to the manufacturers’
protocols and 25 pmol of gene-specific primer pair
(Sigma-Genosys).
Specific PCR products (150–250 bp in length) for each gene
analyzed were designed using Primer3 software (21). Primers
were: GAGATCCCTGCGGAGAAGGT and ATTGGCCAC-
ATCGCTTGTCT for L-type prk; CATCTGTGCCCGTCTG-
GATT and CCAAGGGATCACAAGGGATG for Tmem27;
TTACGGAAGGCCAAGCAAGA and GGGCTTCTCTGAC-
GTGGCTA for Bmp-3; GCGTAGTCCCAAGCATCACC and
ACAGTCCCCGTGGCAGTAGA for Bmp-4; AACAGCACC-
TTTGTGGTCCT and GTGCAGCACTGATCCACAAT for
Ins1; and AGCCATCCAGGCTGTGTTGT and CAGCTGT-
GGTGGTGAAGCTG for -actin.
Western Blotting—Cells were lysed in lysis buffer (62.5 mM
Tris-Cl (pH 6.8), 2% SDS, 10% glycerin, and protease inhibitor
mixture (Sigma)). Protein content was determined using the
Pierce BCAMicro ProteinAssay kit (Thermo Fisher Scientific).
Samples were supplemented with 2-mercaptoethanol and
denatured at 95 °C for 5 min. 20–50 g of protein were sepa-
rated by SDS-PAGE and blotted to nitrocellulose membranes
(Protean BA 85; Schleicher & Schuell). The membranes were
blocked with 1% BSA in Tris-buffered saline for 2 h at room
temperature. Blots were probed with the following primary
antibodies: goat polyclonal antibody to HNF1A (Santa Cruz
Biotechnology, Santa Cruz, CA), diluted 1:1,000; mouse mono-
clonal anti--actin antibody (clone DM 1A; Sigma), diluted
1:5,000; polyclonal anti-BMP-3 antibody (H-73) (Santa Cruz
Biotechnology), diluted 1:1,000; polyclonal anti-insulin anti-
body (H-86) (Santa Cruz Biotechnology), diluted 1:1,000;
monoclonal anti-phospho-SMAD2/3 (Ser465/Ser467) (Cell Sig-
naling Technology), diluted 1:1,000; rabbit polyclonal anti-
phospho-SMAD1/5/8 (Ser463/Ser465//Ser426/Ser428), diluted
1:1,000; rabbit polyclonal anti-BMP-R2 antibody (H-300; Santa
Cruz Biotechnology); and rabbit polyclonal anti-ALK-4 anti-
body (H-75) Santa Cruz Biotechnology), were diluted 1:1,000 in
Tris-buffered saline containing 1% BSA. Antibodies were incu-
bated overnight at 4 °C. The secondary antibodies were perox-
idase-coupled goat anti-rabbit IgG (Sigma) or goat anti-mouse
(Jackson Immunoresearch) diluted 1:10,000 in the same buffer.
Antibody-conjugated peroxidase activity was visualized using
the SuperSignal chemiluminescence reagent (Pierce) and
imaged using a FujiFilm LAS-3000 imaging system (Fuji, Shef-
field, UK).
Transfections and Luciferase Assays—A 2-kb fragment 5 to
exon 1 of the rat Bmp-3 gene was cloned using Kpn1 and
HindIII restriction sites into the pGL3-basic vector (Pro-
mega) to generate the Bmp-3 promoter plasmid. For trans-
fection analyzes, 105/cm2 INS-1 cells were seeded onto
6-well plates in RPMI 1640 medium 1 day prior to transfec-
tion. The cells were transfected with 4 g of BMP-3 pro-
moter plasmid using Lipofectamine 2000 (Invitrogen).
Transfected cells were induced with doxycycline for 24 h and
48 h before harvesting. Reporter activity was measured using
the Dual Luciferase Reporter Assay System (Promega) and
normalized to Renilla luciferase activity. Experiments were
carried out in triplicate and repeated three times. Data are
presented as n-fold expression of Bmp-3 promoter activity
compared with non-induced controls.
Chromatin Immunoprecipitation Assay—Approximately
105/cm2 INS-1 cells were seeded onto 10-cm dishes in RPMI
1640 medium 1 day prior to treatment. The cells were induced
with doxycycline for 48 h in 6 mM glucose to overexpress
WT-HNF1A. Cells were harvested and resuspended in 10ml of
ice-cold PBS, and proteins and DNAwere cross-linked with 1%
formaldehyde for 10min at 37 °C followed by quenching with 2
mM glycine. Cells were pelleted and resuspended in 500 l of
sonication buffer (1% Triton X-100, 0.1% deoxycholate, 50 mM
Tris-Cl (pH 8.0), 150 mM NaCl, 0.1% AEBSF, 1% SDS). Cells
were sonicated for 5 s on ice using a Branson Digital Sonifier
250 (Danbury, CT). Correct shearing of the DNA was con-
firmed on an agarose gel to ensure fragments were in the range
of 200–500 bp. Samples were added to 1 ml with sonication
buffer and precleared with a 50% slurry of protein A/G-agarose
(Santa Cruz Biotechnology) containing 2g of fish spermDNA
and 1% FCS on a rotary wheel for 30 min. The beads were
removed by centrifugation and the supernatant collected and
incubated with 5 g of either a rabbit polyclonal anti-HNF1
antibody (SantaCruzBiotechnology) or an isotype control anti-
body overnight on a rotary wheel at 4 °C in the presence of 2g
of fish spermDNA, 1% FCS, and 45l of a 50% slurry of protein
A/G-agarose. The beads were pelleted by centrifugation and
washed sequentially with PBS, sonication buffer, TSE I buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20mMTris-HCl, pH
8.1, 150mMNaCl), TSE II buffer (same as TSE Iwith addition of
500 mM NaCl), TSE III buffer (0.25 mM LiCl, 1% NP-40, 1%
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1) and fol-
lowed by a final wash in PBS. The DNA including control input
was extracted with 300 l of extraction buffer (1% SDS, 0.1%
NaHCO3) and incubated at 65 °C for 4 h to reverse cross-links
followed by purification using the Qiagen PCR purification kit
according to the manufacturer’s instructions. PCR was per-
formed using the following primers which yielded a PCR prod-
uct of 249 bp: sense, 5-TAGGGCAACAAATTGTGCAG-3;
antisense, 5-TGCTCTTTCTCGGTTGTGTG-3.
Immunohistochemistry—Paraffin-embedded pancreatic sec-
tions from transgenic mice expressing a DN-HNF1A mutant
under the control of rat insulin promoter DN-HNF1A and con-
trol wild-typeC57BL/6JBomTacmice-were deparaffinized (22)
and incubated overnight at 4 °C with the rabbit polyclonal anti-
BMP-3 (Santa Cruz Biotechnology) diluted 1:20). Slides were
incubated for 1 h at room temperature in Alexa Fluor 568-
labeled anti-rabbit secondary antibody (Molecular Probes)
(1:200). Slides were incubated again overnight at 4 °C with
the second primary guinea pig anti-insulin antibody (Dako-
Cytomation A0564; 1:20) followed by 1 h at room temperature
in FITC labeled anti-goat secondary antibody (Jackson Immu-
noresearch; 1:200) and mounted in Vectashield with DAPI
(Vector Shield, Vector Laboratories). Images were taken with a
Zeiss LSM710 confocal microscope equipped with a 40  1.3
NA oil immersion objective (Carl Zeiss). FITC was excited at
488 nm with an argon laser, using a 488/543-nm multichroic
beam splitter; the emission was collected at a 490- to 550-nm
spectral band. Rhodamine was excited at 543 nmwith a helium
neon laser, using the same beam splitter, and the emission was
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collected at a 570–650-nm spectral band. DAPI was excited
using the 405-nmDPSS laser and a 405-nmdichroic beam split-
ter. DAPI fluorescence was detected in the 420–480-nm spec-
tral band. Images were processed using ImageJ software.
Digital pictures were taken of islets of Langerhans, recog-
nized by their distinct morphology. Immunohistochemistry of
mousepancreatic slice cultureswasconductedasdescribedabove.
Insulin expression levels were assessed by measuring the fluores-
cence intensity of antibody staining in islets across the optical
slices. Image z-stacks were taken using an LSM 5 live equipped
with a 40 1.3NA oil immersion objective using a 489-nmDPSS
laser for excitationof FITC (CarlZeiss). Theoptical slice thickness
was set to 1.8 nm; fluorescence emission was detected at 495–555
nm.Hoechst stainingwas assessed as a reference for nuclei. Stacks
of optical slices were taken at intervals of 1 m. Resultant image
stacks were analyzed using ImageJ. Themean fluorescence inten-
sity of an islet and the intensity of the islet cells peripheral to the
slice were determined. Intensity of insulin staining was calculated
as thepercentof average islet intensity.Datawereaveraged fromat
least three similarly treated slices, and the experiment was
repeated with similar results.
Statistics—Results were expressed asmeans S.E. Statistical
analysis was conducted using the SPSS version15.0 software
package for Windows (SPSS Inc.). Differences between treat-
ments were analyzed by Student’s t test, the Mann-Whitney U
test, or one-way analysis of variance (ANOVA) with post hoc
Tukey-Kramer multiple comparison test. Differences were
considered to be significant at p 0.05.
RESULTS
Microarray Analysis of the Transcriptional Response of Rat
INS-1 Cells Inducibly Expressing the Pro291fsinsC-HNF1A
Frameshift Mutation—The time course of hnf1a gene induc-
tion in Pro291fsinsC-HNF1A INS-1 cells is represented by
absolute qPCR (Fig. 1A). Data are presented as cDNA copy
number/l of the hnf1a gene expression. Data are represented
as means  S.E. from n  3 cultures. The experiment was
repeated three times with similar results. * p  0.05 indicates
the difference from non-induced controls.
In non-induced INS1 cells no increase in Pro291fsinsC-
HNF1A gene expression in copies/l was detected. Western
blot analysis confirmed the induction of Pro291fsinsC-HNF1A
(Fig. 1B). Concomitant with the induction of the Pro291fsinsC-
HNF1A mutant was a significant reduction in mRNA levels of
L-type pyruvate kinase gene (Fig. 1C) and Tmem27 (Fig. 1D),
both known HNF1A target genes, confirming previous results
in this cellular system (17, 23–25).
Using an unbiased microarray approach (Affymetrix
GeneChip, Rat RG-U34A) to investigate transcriptome
changes in INS-1 cells following induction of the mutant pro-
tein for 24 h we identified several genes with altered expression
in response to Pro291fsinsC-HNF1A. Cutoff for up-regulated
genes was set at 2.0-fold and 0.5-fold for down-regulated genes.
Differentially expressed genes of interest were classified into
distinct functional subgroups. These included metabolic regu-
lation, signal transduction, transport activity, differentiation,
inflammatory response, and regeneration of beta cells (Table 1).
FIGURE 1. Induction ofHnf1a gene expression in Pro291fsinsC-HNF1A INS-1 cells with subsequentmRNA expression analysis. A, Pro291fsinsC-HNF1A
INS-1 cells were inducedwith doxycycline for 0–48 h, andHnf1a gene expressionwas determined using absolute real-time qPCR. Data are presented as cDNA
copy number/l of theHnf1agene expression. Data are represented asmeans S.E. (error bars) from n 3 cultures. The experimentwas repeated three times
with similar results. *, p  0.05 indicates the difference from non-induced controls. B, cells were treated as described above, and whole cell lysates were
analyzedbyWestern blotting on 12%SDS-PAGE.Membraneswere probedwith a polyclonal antibody recognizingHNF1A.-Actin served as a loading control.
C and D, Pro291fsinsC-HNF1A INS-1 cells were treated as in A, and L-type Prk gene mRNA expression (C) and Tmem27mRNA expression (D) were determined
using real-time qPCR. Experiments were carried out in triplicate, repeated three times, and normalized to -actin. Data are represented as mean S.E., and
statistical analysis was carried out as in A. *, p 0.05 compared with non-induced controls.
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Expression levels of selected genes were confirmed by real-time
qPCR techniques (supplemental Fig. 1).
Among the genes identified in this microarray study were
several known target genes of HNF1A including Pklr, Foxa3,
and Pdk-1, and all were found to be down-regulated in response
to Pro291fsinsC-HNF1A (16, 17, 26, 27). Foxa2, which is sub-
ject to transcriptional repression by HNF1A (28), was found to
be up-regulated. Interestingly, a number of potential novel tar-
get genes regulated by HNF1A were also identified on the Rat
RG-U34A microarray. In particular, we observed a significant
down-regulation of the TGF- superfamily member BMP-3 as
well as up-regulation of Cd36 and PAP III.
Suppression of the Bmp-3 Gene and Protein Expression in
INS-1 Cells Inducibly Expressing the Pro291fsinsC-HNF-1A
Frameshift Mutation—BMPs are members of the TGF-
superfamily, a large family of growth factors, including TGF-
and activins. They are critically involved in tissue differentia-
tion and development and signal via type I and type II TGF-/
BMP receptors (9). To validate the down-regulation of Bmp-3
mRNA expression, we examined its expression by qPCR. Anal-
ysis of Bmp-3mRNA expression revealed a significant time-de-
pendent decrease in expression in Pro291fsinsC-HNF1A cells,
evident from 8 h onward (Fig. 2A). In contrast, INS-1 cells
inducibly expressing WT-HNF1A cells showed a time-depen-
dent increase in Bmp-3 gene expression (Fig. 2B). Down-regu-
lation of Bmp-3mRNA expression was also observed in INS-1
cells expressing the artificial dominant negative HNF1A
mutant (SM6) (Fig. 2C).
We next investigated the specificity of Bmp-3 down-regula-
tion compared with other members of the TGF- superfamily.
Several members of the TGF- superfamily, including recep-
tors and downstream signal transducers, were present on the
chip and remained unchanged from the Affymetrix Gene array
data (Bmp-2-like, Bmp-4, Bmp-6, Bmp-7, and Bmp-type IA
receptor, type III Tgf- receptor gene, LTBP-3, LTBP-2, the
Smads1–3, and Smads7 and 8 (Table 2). However, because
BMP-4 has previously been identified to be involved in pancre-
atic function (29), it was therefore further analyzed by qPCR.
Bmp-4mRNAexpressionwas not altered during Pro291fsinsC-
HNF1A induction (Fig. 2D). Furthermore, qPCR analysis was
also performed on several members of the TGF- superfamily
members (Tgf-1, Tgf-2, Tgf-3, and activin -A and activin
-B) and demonstrated that there was no prominent down-
regulation of other genes of the TGF- superfamily at either 8 h
or 16 h (supplemental Fig. 2).
We also investigated BMP-3 protein levels by Western blot-
ting in INS-1 cells inducibly expressing either Pro291fsinsC-
HNF1A orWT-HNF1A. BMP-3 protein expression was signif-
icantly reduced upon induction of Pro291fsinsC-HNF1A
mutant at 8, 16, and 24 h compared with non-induced controls
with expression virtually absent at 48 h (Fig. 2E). Expression of
WT-HNF1A resulted in increased expression of BMP-3protein
(Fig. 2F). These data suggested that BMP-3 expressionwas con-
trolled by HNF1A.
HNF1A Represses Bmp-3 Promoter Activity in INS-1 Cells
Inducibily Expressing the Pro291fsinsC-HNF1AMutation—We
next investigated whether the HNF1Amutant directly reduced
Bmp-3 promoter activity. A 2-kb fragment of Bmp-3 sequence
5 to the transcription initiation site was identified by the
ENSEMBL database and cloned into the pGL3 basic vector. To
assess the effects of HNF1A expression on the activity of
the Bmp-3 promoter we transfected WT-HNF1A and
Pro291fsinsC-HNF1 INS-1 cells with the promoter construct
and monitored the relative luciferase expression levels follow-
ing induction for 24 and 48 h. Luciferase activity assays demon-
strated thatWT-HNF1A significantly increased the trans-acti-
vation of the Bmp-3 promoter (Fig. 3A), whereas the induction
of the Pro291fsinsC-HNF1A mutation decreased the trans-ac-
tivation of the Bmp-3 promoter compared with non-induced
controls (Fig. 3B). To investigate whether the effects of HNF1A
on theBmp-3 promoter weremediated via direct binding to the
promoter we first examined the putative promoter sequence
for HNF1A binding sites. Using the ALGGEN Promo database,
we identified a potential HNF1A binding site in the Bmp-3 pro-
moter fragment (Fig. 3C). To assess whether HNF1A could
bind within this region we performed ChIP experiments using
an HNF1A antibody or an IgG isotype control. As demon-
strated in Fig. 3C, amplification of a region encompassing the
identified HNF1A binding site was evident in WT-HNF1A
overexpressing cells but not in non-induced or IgG controls
(Fig. 3D). Taken together, these data suggest that HNF1A can
bind the Bmp3 promoter directly.
TABLE 1
Differentially expressed genes classified into distinct functional
subgroups
Accession Gene
Down-regulated genes
Signal transduction
X13905cds Ras-related protein 1B
rcAA859896 Myristoylated alanine-rich protein
kinase C substrate
D49785 Mitogen-activated protein kinase 12
X13905cds Ras-related protein 1B
Metabolic regulation
X05684 L-type pyruvate kinase
NM 0538262 Pyruvate dehydrogenase kinase
M73714 Aldehyde dehydrogenase family 3
Transcription factors
AB017044 Forkhead box A3
Growth factor and differentiation
S77492i and D63860 Bone morphogenic protein 3
M93257s Interleukin 6
Cytoskeletal proteins/transport
activity
rcAA866465s Tropomyosin 3
rcAI145444 Neurabin 1
U14398 Synaptotagmin IV
Up-regulated genes
Signal transduction
AF072439 Growth hormone-releasing
hormone
M93257s Catechol-O-methytransferase
Metabolic regulation 3-Hydroxysteroid dehydrogenase
D17310s
Transcription factors
X55955 Forkhead box A1
NM 012742 Forkhead box A2
Transport activity
AB013112s Aquaporin 9
D13962 Solute carrier family 22
Growth factor and differentiation
L20869 Pancreatitis-associated protein III
U93306 VEGF receptor
U69278 Ephrin receptor
Inflammation
L22190 Serum amyloid A
D50558g CD86 antigen
AF072411 CD36 antigen
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BMP-3 Is Expressed in Beta Cells in Mouse Pancreas and Stim-
ulates Insulin Expression in INS-1 Cells and Beta Cells—
Because a physiological role for BMP-3 in the pancreas has not
yet been described, we next investigated whether BMP-3 and
insulin were co-expressed in beta cells in vivo. Therefore, we
performed immunohistochemistry on pancreatic tissue from
rat insulin promoter DN-HNF1A and control wild-type
C57BL/6JBomTac mice (22). The populations of beta cells
immunopositive for insulin also showed prominent reactivity
against BMP-3 and demonstrated a strong co-localization of
BMP-3 and insulin in the islets from wild-type mice (Fig.
4A). In contrast, DN-HNF1A islets showed significantly
reduced expression of BMP-3 in islet cells (Fig. 4). Moreover,
reduced expression of BMP-3 correlated with reduced levels
of insulin expression.
Control experiments demonstrated the expression of the
canonical BMP receptors, BMP-R2 and ALK-4, in INS-1 cells
(see Fig. 6, B and C). Next we explored the possibility that
BMP-3 was involved in the regulation of insulin expression.
TheTGF- type I/activin-receptor like serine/threonine kinase
(ALK) signaling pathways initiate the ligand-induced phosphor-
ylation of the receptor-SMAD proteins in their C termini (10).
The canonical activation pathway of SMADs 1, 5, and 8 involves
phosphorylation by BMP receptors, whereas SMAD2 and 3 are
activated by TGF-s, activins and BMP-3, respectively (30, 31).
Indeed, treatment of parental INS-1 cells with 10 ng/ml of
recombinant BMP-3 showed an increase in the C-terminal
phosphorylation of SMAD2/3 (Fig. 5A). In contrast, treatment
of parental INS-1 cells with 10 ng/ml recombinant human
FIGURE 2. BMP-3 and BMP-4 expression in INS-1 cells. Pro291fsinsC-HNF1A INS-1 cells, WT-HNF1A cells, and DN-HNF1A cells were treated with 500 ng/ml
doxycycline for 8, 16, 24, and 48 h as indicated. Cells were harvested and total RNA isolated. Bmp-3 (A–C) or Bmp-4 (D) mRNA expressionwas determined using
real-time qPCR following normalization to-actin. Experimentswere carried out in triplicate and analyzed using one-way ANOVAwith post hoc Tukey-Kramer
test. Data are represented as mean S.E. (error bars), and statistical analysis was carried out as in A. *, p 0.05 compared with non-induced controls. E and F,
Pro291fsinsC-HNF1A INS-1 cells were treated as above and harvested for protein. Whole cell lysates were analyzed by Western blotting on 15% SDS-PAGE.
Membranes were probed with an anti-BMP-3 polyclonal antibody. Probing with -actin served as a loading control.
TABLE 2
Members of the TGF- superfamily present on the Affymetrix
GeneArray
Accession Gene Change
D63860 and S77492 BMP-3 Decreased
U66298 BMP-6 No change
Z22607 BMP-4 No change
D29769 BMP-7 No change
S75359 Bone morphogenetic protein
type IA receptor
No change
L20678 BMP-2-like No change
M80784 Type III TGF- receptor No change
M96643 TGF-2 No change
X52498 TGF-1 No change
AF016900 Latent TGF3--binding protein 3 No change
AF016901 Latent TGF3-binding protein 2 No change
AF067727 and U66478 SMAD1 No change
AB017912 SMAD2 No change
AF042499 SMAD7 No change
AF012347 SMAD8 No change
U66479 SMAD3 No change
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BMP-4 did not show any increased phosphorylation of
SMAD2/3 (Fig. 5B), but instead increased the phosphorylation
of SMAD1/5/8 (Fig. 5C), demonstrating the specificity of the
BMP-3/SMAD2 response. Treatment of parental INS-1 cells
with rBMP-3 potently increased insulin protein (Fig. 5D) and
gene expression (Fig. 5E). Furthermore, murine organotypic
pancreatic slice cultures treated with rBMP-3 for 24 h had sig-
nificantly increased insulin immunofluorescence compared
with control treated slices (Fig. 5, F and G).
Treatment with Recombinant BMP-3 Reverses the
Pro291fsinsC-HNF1A-induced Decrease in Insulin Expression—
We next determined whether exogenous BMP-3 could reverse
the Pro291fsinsC-HNF1A-induced decrease in insulin gene
expression previously observed in INS-1 cells (32). Western
blotting experiments revealed a prominent down-regulation in
the levels of phosphorylated SMAD2/3 upon induction of the
mutant (Fig. 6A), demonstrating that indeed signaling through
SMAD2 was significantly disturbed after the induction of
Pro291fsinsC-HNF1A. In contrast, we found no evidence for a
down-regulation of BMP-R2 (Fig. 6B) or ALK-4 protein levels
(Fig. 6C). Next, Pro291fsinsC INS-1 cells were simultaneously
treated with doxycycline and 10 ng/ml rBMP-3 for 24 h. Treat-
ment of INS-1 cells inducibly expressing the Pro291fsinsC-
HNF1A or DN-HNF1A mutant with 10 ng/ml rBMP-3 was
sufficient to prevent the decrease in insulin gene expression
(Fig. 6, D and E). In agreement with these data, the C-terminal
phosphorylation of SMAD2/3 was significantly increased in
Pro291fsinsC-HNF1A-expressing cells after treatment with 10
ng/ml rBMP-3 (Fig. 6F).
DISCUSSION
The present study demonstrates several important find-
ings contributing to the understanding of mutant HNF1A-
induced defects in the expression of genes involved in tissue
differentiation and homeostasis. These include (i) the induc-
ible expression of the common, frameshift mutation,
Pro291fsinsC-HNF1A leads to the potent down-regulation
FIGURE 3.Repression of BMP-3 promoter activity in Pro291fsinsC-HNF1A INS-1 cells. A and B, WT-HNF1A (A) and Pro291fsinsC-HNF1A (B) INS-1 cells were
transfectedwith a vector containing the firefly luciferase gene under control of the BMP-3 promoter alongside a Renilla luciferase reporter plasmid (pRL-TK) as
an internal transfection control. INS-1 cells were treatedwith doxycycline (Dox; 500 ng/ml) for 24 or 48 h. Luminescence activity was normalized to the activity
of the co-transfected RL-TK-luc and expressed as -fold of increasewith respect to controls. Experiments were repeated three times. Statistical significancewas
determined using one-way ANOVA with post hoc Tukey-Kramer multiple comparison test. *, p 0.05 compared with non-induced controls. C, schematic of
BMP-3 promoter and the identified potential HNF1A binding site is shown. The HNF1A binding site is identified in block capitals, and the base pair numbers
indicated are relative to the start of the first exon. D, WT-HNF1A INS-1 cells were treated with 500 ng/ml doxycycline for 48 h. Non-induced INS-1 cells served
as a control. Cells were harvested and fixed, and ChIP was performed using an HNF1A antibody or an IgG isotype control. The enrichment of the HNF1A target
site was assessed by PCR with a specific primer set that spanned the identified HNF1A binding site. Samples were run on 2% agarose gel. Experiments were
repeated twice with similar results. Error bars, S.E.
FIGURE 4. BMP-3 and Insulin co-localization in pancreatic islets in vivo.
A, paraffin-embedded pancreatic sections from 3-month-old wild-type
C57BL/6JBomTac control mice and rat insulin promoter DN-HNF1A trans-
genic mice were double stained using antibodies against BMP-3 and insulin.
Primary antibodies were recognized by secondary antibodies coupled to
AlexaFluor 568 (red) for BMP-3and toFITC (green) for insulin, respectively. Cell
nuclei were stainedwith DAPI. Confocal imageswere taken using 1-m-thick
optical section. Scale bar, 50 m. In islets derived from WT animals the aver-
age pixel intensity of the BMP-3 fluorescence was significantly higher than in
transgenic mice (TG). Data are represented as means  S.E. (error bars);
*p0.05,Mann-WhitneyU test;n39 (WT) and35 (TG) pooled from three
separate animals.
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of Bmp-3 at the mRNA and protein level in insulin-secreting
INS-1 cells; (ii) Dual Luciferase Reporter assays reveal that
the HNF1A mutant reduces Bmp-3 promoter activity, which
results in the decrease in the transcriptional activity of the
Bmp-3 gene and corresponding protein expression; (iii)
mouse islet cells express BMP-3 in beta cells; (iv) treatment
of INS-1 cells and organotypic pancreatic slice cultures with
exogenous recombinant BMP-3 increases protein levels of
insulin; and (v) treatment of INS-1 cells with BMP-3 com-
pletely rescues the decrease in insulin expression induced by
the HNF1A frameshift mutation. Our study therefore sug-
gests a new role for the TGF- superfamily member BMP-3
in the regulation of insulin production and indicates that loss
of BMP-3 function may be involved in the pathophysiology
of HNF1A-MODY.
Given the importance of beta cell dysfunction in HNF1A-
MODY, we utilized high density oligonucleotide microarrays
and real-time qPCR techniques to carry out an unbiased anal-
ysis of HNF1A-induced defects in the expression of novel genes
involved in beta cell function, differentiation, and regeneration.
Interestingly, this Genechip array, in combination with dCHIP
software, identified several known and multiple putative novel
HNF1A target genes down-regulated in INS-1 cells inducibly
expressing the Pro291fsinsC-HNF1A mutant. We also found
several genes to be significantly up-regulated in response to
Pro291fsinsC-HNF1A induction, which could be a result of
compensatory or complex gene regulation. Among the genes
identified, we found a significant effect of the HNF1A mutant
on the expression of Bmp-3. Subsequent qPCR analyses sug-
gested Bmp-3 to be a novel HNF1A target gene. To understand
the regulation of expression of Bmp-3, we cloned and
sequenced a 2.0-kb promoter fragment of the Bmp-3 gene 5 to
the transcription initiation site which was identified using the
ENSEMBL database. Notably, Dual Luciferase Reporter assay
experiments showed that induction of the Pro291fsinsC-
HNF1A frameshift mutation decreased the transcriptional
activity of the Bmp-3 promoter significantly compared with
non-induced controls, suggesting that the BMP-3 cytokine is a
direct transcriptional target of physiological HNF1A activity.
Indeed, we could demonstrate enriched binding of HNF1A to a
region within the Bmp-3 promoter with a potential HNF1A
binding site.
BMP-3 and other members of the TGF- superfamily
mediate gene expression in diverse cell types and are
involved in a wide range of biological functions in the pan-
creas, including cell proliferation, differentiation, neogene-
sis, and apoptosis (9, 10, 33). BMP-3 was originally thought
to be a trophic factor required for bone growth because of its
ability to induce bone and cartilage development (34). How-
ever, subsequent gene targeting studies revealed that BMP-3
is indeed antiosteogenic, but plays an instructive role during
early pancreatic development (35, 36). Activated TGF-
superfamily members signal via dual type II and type I trans-
membrane/activin-like kinase serine/threonine kinase re-
ceptors and effector SMAD transcription factors (9, 10).
Ligand binding and subsequent receptor activation lead to
the phosphorylation and activation of SMADs which trans-
locate to the nucleus and regulate the transcription of tar-
get genes. The ligand-specific SMADs, SMAD1, SMAD2,
SMAD3, and SMAD5, are phosphorylated by activated type I
TGF- receptors. SMAD1 and SMAD5 are specific for all
members of the BMP family of proteins except BMP-3.
BMP-3 signals through phosphorylation of the SMADs2/3,
similar to TGF-s and activins (30, 31). It has been reported
previously that TGF-1 promotes the development of endo-
crine cells such as insulin-containing beta cells (37) and that
activin receptor inactivation in pancreatic beta cells leads to
the development of diabetes (12, 38). We here demonstrate a
significant disturbance of BMP-3/SMAD2 signaling axis in
response to the expression of Pro291fsinsC-HNF1A, which
FIGURE 5. Increased insulin expression following treatment with
rBMP-3. A–D, parental INS-1 cells were precultured in reduced serum
overnight and treated with 10 ng/ml rBMP-3 for 10, 30, and 120 min or 10
ng/ml rBMP-4 for 1 h in 0.05% serum medium with 6 mM glucose as indi-
cated. Whole cell lysates were analyzed by Western blotting. Membranes
were probed with polyclonal antibodies raised against phosphorylated-
SMAD2 (A and B), phosphorylated SMAD1/5/8 (C), or insulin (D). Anti--
actin immunoreactivity served as loading control. E, parental INS-1 cells
were precultured in reduced serum overnight and treated with 10 ng/ml
rBMP-3 for 10, 30, and 120min in 0.05% serummediumwith 6mM glucose.
After treatment, mRNA expression of insulin gene was analyzed by real-
time qPCR. Expression levels were normalized to controls. Data are repre-
sented as means S.E. (error bars) from n 3 cultures.*, p 0.05 different
from controls. F and G, mouse organotypic pancreatic slice cultures were
incubated for 24 h with 50 ng/ml rBMP-3 or vehicle and stained with
anti-insulin antibody (green); nuclei were counterstained with Hoechst
(blue). Quantification of insulin immunofluorescence staining intensity
was evaluated from confocal stacks of 20 islets per treatment in three
independent experiments. Islets treated with rBMP-3 show significant
higher levels of peripheral insulin staining. Data are represented as
mean S.E., and statistical analysis was carried out using the Mann-Whit-
ney U test. *, p 0.05 compared non-treated controls. Scale bar, 50 m.
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was reversed upon reintroduction of BMP-3. It is therefore
conceivable that signaling through SMAD2 and SMAD3 is of
vital importance for differentiation and maintenance of beta
cell function. In support of these data, previous work has
demonstrated that the conditional, pancreas-specific ex-
pression of the inhibitory SMAD7 protein, which inhibits
TGF-, activin, and BMP signaling, induces a reversible dia-
betic phenotype in mice (39, 40).
In contrast to BMP-3, we found little evidence for a dysregula-
tion of other TGF- superfamily members after induction of the
Pro291fsinsC-HNF1Amutation, including BMP-4. An important
role for BMP-4 and its receptor BMPR1a in beta cell function has
been demonstrated previously (29). Using gene targeting
approaches, mice with diminished BMP-4/BMPR1A signaling in
betacells showeddecreasedexpressionofgenes involved in insulin
production and release, glucose sensing, and secretion-stimulus
coupling, as well as incretin signaling. These mice eventually
developed diabetes due to impaired insulin secretion. Our data
suggested that in the context of HNF1A-MODY and defective
HNF1A signaling, BMP-3 signaling rather than BMP-4-induced
pathways appears to be primarily disturbed.
Of note, further experiments demonstrated that BMP-3 was
sufficient to activate insulin expression in INS-1 cells as well as in
pancreatic islets. Treatment with BMP-3 also reversed the
decrease in insulin expression after Pro291fsinsC-HNF1A induc-
tion, suggesting that repression of the Bmp-3 promoter led to the
subsequent disturbance of insulinmRNA and protein expression.
However, it should also be stated that the insulin gene promoter
has direct HNF1A binding sites (17) which contribute to the
decrease in insulin gene expression in response to Pro291fsinsC-
HNF1A induction. Indeed, the insulin gene promoter is subject to
a complex transcriptional regulation (41), and furtherwork is nec-
essary to determine the possible interaction between promoter
elements and BMP-3/SMAD2 signaling in the regulation of insu-
lin gene transcription.
In conclusion, our studies suggest a critical link between
HNF1A-MODY-induced alterations in gene expression and
growth factors of theTGF- superfamily that control tissuediffer-
entiation and gene expression.We further propose that the BMP-
3/SMAD2pathwaymay play a role in regulating beta cell function
andmay hence present a new therapeutic target for the treatment
of HNF1A-MODY or type 2 diabetes.
FIGURE 6. Treatment of INS1 cells with recombinant BMP-3 protein reverses the insulin-deficiency phenotype in HNF1A-MODY cells. A–C, INS-1 cells
were incubated with doxycycline for 8, 16, 24, and 48 h to induce the expression of the Pro291fsinsC-HNF1Amutant protein. Cells were harvested for protein,
and whole cell lysates were analyzed by Western blotting. Membranes were probed with polyclonal antibodies directed against phosphorylated-SMAD2 (A),
BMP-receptor 2 (B), or activin-like-kinase-receptor-4 (C). -Actin was used as a loading control. D and E, INS-1 cells were cultured in 2% serum overnight. Cells
were inducedwith doxycycline (Dox) to overexpress the Pro291fsinsC-HNF1Amutant (D) or DN-HNF1Amutant (E) and treatedwith 10 ng/ml rBMP-3 in 0.05%
serum at 6 mM glucose for 24 h. Cells were harvested for RNA, and insulin gene expression was analyzed by real-time qPCR and normalized to -actin.
Experiments were carried out in triplicate. Data are represented as mean S.E. (error bars). *, p 0.05 different from non-induced controls. F, Pro291fsinsC-
HNF1A INS-1 cells were induced with doxycycline for 24 h. Cells were then treated with 10 ng/ml of rBMP-3 for 20, 30, 60, 120, and 240min. Whole cell lysates
were analyzed by Western blotting. Membranes were probed with a polyclonal antibody raised against phosphorylated-SMAD2, and -actin served as a
loading control.
BMP-3 Controls Insulin Gene Expression
JULY 22, 2011•VOLUME 286•NUMBER 29 JOURNAL OF BIOLOGICAL CHEMISTRY 25727
REFERENCES
1. Fajans, S. S. (1990) Diabetes Care 13, 49–64
2. Bell, G. I., and Polonsky, K. S. (2001) Nature 414, 788–791
3. Yamagata, K., Furuta, H., Oda, N., Kaisaki, P. J., Menzel, S., Cox, N. J.,
Fajans, S. S., Signorini, S., Stoffel, M., and Bell, G. I. (1996) Nature 384,
458–460
4. Frayling, T.M., Evans, J. C., Bulman,M. P., Pearson, E., Allen, L., Owen, K.,
Bingham, C., Hannemann, M., Shepherd, M., Ellard, S., and Hattersley,
A. T. (2001) Diabetes 50, S94–100
5. Byrne, M. M., Sturis, J., Menzel, S., Yamagata, K., Fajans, S. S., Dronsfield,
M. J., Bain, S. C., Hattersley, A. T., Velho, G., Froguel, P., Bell, G. I., and
Polonsky, K. S. (1996) Diabetes 45, 1503–1510
6. Lehto,M., Tuomi, T.,Mahtani,M.M.,Wide´n, E., Forsblom, C., Sarelin, L.,
Gullstro¨m,M., Isomaa, B., Lehtovirta,M., Hyrkko¨, A., Kanninen, T., Orho,
M., Manley, S., Turner, R. C., Brettin, T., Kirby, A., Thomas, J., Duyk, G.,
Lander, E., Taskinen, M. R., and Groop, L. (1997) J. Clin. Invest. 99,
582–591
7. Weir, G. C., and Bonner-Weir, S. (2004) Diabetes 53, S16–21
8. Bouwens, L., and Rooman, I. (2005) Physiol. Rev. 85, 1255–1270
9. Attisano, L., and Wrana, J. L. (2002) Science 296, 1646–1647
10. Feng, X.H., andDerynck, R. (2005)Annu. Rev. Cell Dev. Biol. 21, 659–693
11. Massague´, J., Blain, S. W., and Lo, R. S. (2000) Cell 103, 295–309
12. Rane, S. G., Lee, J. H., and Lin, H. M. (2006) Cytokine Growth Factor Rev.
17, 107–119
13. Ball, E. M., and Risbridger, G. P. (2001) Dev. Biol. 238, 1–12
14. Jiang, F. X., Stanley, E. G., Gonez, L. J., andHarrison, L. C. (2002) J. Cell Sci.
115, 753–760
15. Wobser, H., Du¨ssmann, H., Ko¨gel, D., Wang, H., Reimertz, C., Wollheim,
C. B., Byrne, M.M., and Prehn, J. H. (2002) J. Biol. Chem. 277, 6413–6421
16. Wang, H., Maechler, P., Hagenfeldt, K. A., and Wollheim, C. B. (1998)
EMBO J. 17, 6701–6713
17. Wang, H., Antinozzi, P. A., Hagenfeldt, K. A.,Maechler, P., andWollheim,
C. B. (2000) EMBO J. 19, 4257–4264
18. Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A., and Wollheim, C. B.
(1992) Endocrinology 130, 167–178
19. Bonner, C., Bacon, S., Concannon, C. G., Rizvi, S. R., Baquie´, M., Farrelly,
A. M., Kilbride, S. M., Dussmann, H., Ward, M. W., Boulanger, C. M.,
Wollheim, C. B., Graf, R., Byrne, M. M., and Prehn, J. H. (2010) Diabetes
59, 2799–2808
20. Altschul, S. F., Gish,W.,Miller,W.,Myers, E.W., and Lipman, D. J. (1990)
J. Mol. Biol. 215, 403–410
21. Rozen, S., and Skaletsky, H. (2000)Methods Mol. Biol. 132, 365–386
22. Hagenfeldt-Johansson, K. A., Herrera, P. L., Wang, H., Gjinovci, A., Ishi-
hara, H., and Wollheim, C. B. (2001) Endocrinology 142, 5311–5320
23. Akpinar, P., Kuwajima, S., Kru¨tzfeldt, J., and Stoffel, M. (2005)CellMetab.
2, 385–397
24. Fukui, K., Yang, Q., Cao, Y., Takahashi, N., Hatakeyama, H., Wang, H.,
Wada, J., Zhang, Y., Marselli, L., Nammo, T., Yoneda, K., Onishi, M.,
Higashiyama, S., Matsuzawa, Y., Gonzalez, F. J., Weir, G. C., Kasai, H.,
Shimomura, I., Miyagawa, J., Wollheim, C. B., and Yamagata, K. (2005)
Cell Metab. 2, 373–384
25. Miquerol, L., Lopez, S., Cartier, N., Tulliez, M., Raymondjean, M., and
Kahn, A. (1994) J. Biol. Chem. 269, 8944–8951
26. Servitja, J. M., Pignatelli, M., Maestro, M. A., Cardalda, C., Boj, S. F., Lo-
zano, J., Blanco, E., Lafuente, A.,McCarthy,M. I., Sumoy, L., Guigo´, R., and
Ferrer, J. (2009)Mol. Cell. Biol. 29, 2945–2959
27. Farrelly, A. M., Wobser, H., Bonner, C., Anguissola, S., Rehm, M., Con-
cannon, C. G., Prehn, J. H., and Byrne, M. M. (2009) Diabetologia 52,
136–144
28. Wang, H., Gauthier, B. R., Hagenfeldt-Johansson, K. A., Iezzi, M., and
Wollheim, C. B. (2002) J. Biol. Chem. 277, 17564–17570
29. Goulley, J., Dahl, U., Baeza, N., Mishina, Y., and Edlund, H. (2007) Cell
Metab. 5, 207–219
30. Verrecchia, F., Chu, M. L., and Mauviel, A. (2001) J. Biol. Chem. 276,
17058–17062
31. Kawabata, M., Imamura, T., and Miyazono, K. (1998) Cytokine Growth
Factor Rev. 9, 49–61
32. Wobser, H., Bonner, C., Nolan, J. J., Byrne, M. M., and Prehn, J. H. (2006)
Diabetologia 49, 519–526
33. Kim, S. K., and MacDonald, R. J. (2002) Curr. Opin. Genet. Dev. 12,
540–547
34. Sampath, T. K., Muthukumaran, N., and Reddi, A. H. (1987) Proc. Natl.
Acad. Sci. U.S.A. 84, 7109–7113
35. Bahamonde, M. E., and Lyons, K. M. (2001) J. Bone Joint Surg. Am. 83,
S56–62
36. Kim, S. K., and Hebrok, M. (2001) Genes Dev. 15, 111–127
37. Sanvito, F., Herrera, P. L., Huarte, J., Nichols, A., Montesano, R., Orci, L.,
and Vassalli, J. D. (1994) Development 120, 3451–3462
38. Yamaoka, T., Idehara, C., Yano, M., Matsushita, T., Yamada, T., Ii, S.,
Moritani, M., Hata, J., Sugino, H., Noji, S., and Itakura, M. (1998) J. Clin.
Invest. 102, 294–301
39. Kuang, C., Xiao, Y., Liu, X., Stringfield, T. M., Zhang, S., Wang, Z., and
Chen, Y. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 1858–1863
40. Smart, N. G., Apelqvist, A. A., Gu, X., Harmon, E. B., Topper, J. N., Mac-
Donald, R. J., and Kim, S. K. (2006) PLoS Biol. 4, e39
41. Hay, C. W., and Docherty, K. (2006) Diabetes 55, 3201–3213
BMP-3 Controls Insulin Gene Expression
25728 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 29•JULY 22, 2011
